Glioblastoma multiforme (GBM) is a highly aggressive, complex, and devastating form of brain cancer, effecting hundreds of people each day. We believe it is our duty to accelerate progress against this disease so we launched the Defeat GBM Research Collaborative in 2013 with the intent to double the 5 year survival rate of GBM patients. This comes at a time when collaboration is becoming the norm and the abundance of genomic data is accelerating diagnostic, prognostic, and therapeutic progress.
Oligo Research Fund
Oligodendroglioma (oligo) is a relatively rare brain tumor representing about 6% of gliomas, with a diagnosis rate of about 1,150 patients a year in the U.S. alone. Critical research is required to deliver oligo patients new therapies that are more durable and extend their lives. In order to make effective, targeted therapies a reality it is essential to identify and understand the molecular drivers of the tumor’s genesis and maintenance, as well as resistance.
Our new pediatric initiative, Project Impact, will leverage increases in knowledge gained from earlier funded research efforts, and develop a program that can address critical barriers to progress within the drug discovery and development pipeline through an integrated approach to advance research toward new treatments for pediatric brain tumor patients.
The Community Research Fund allows contributors to pool donations to support research on a specific type of tumor. This program leverages a team of highly experienced, nationally-recognized scientific experts, working with National Brain Tumor Society staff, to determine the best investment strategy for each fund.
From the Blog
November 20, 2014
Guest Blog: Why I want you to join us on Dec. 2
August 10, 2010, was a Tuesday. I got confirmation that what my mind and body had been telling me for months, was true. I had a brain tumor. It was a gift that I got the care I needed, and am here today. I got involved with the National Brain Tumor Society to connect with […]Read more |
November 17, 2014
Encouraging Results from Novocure Clinical Trial
Novocure, a company that creates medical devices to treat cancer, announced this weekend that their Novo-TTF-100A system (now being called Optune), in combination with temozolomide (also know as Temodar or TMZ), demonstrated improved survival in newly diagnosed glioblastoma multiforme (GBM) patients in a clinical trial, compared with temozolomide alone. The announcement was made at the […]Read more |
November 7, 2014
Can this treatment help me live a longer and better life?
Why was I asked to sit on a panel with two top officials from the U.S. Food and Drug Administration (FDA), two leading neuro-oncologists, an associate professor of neuropsychiatry, and an executive from the biopharmaceutical company, Genentech? Because, as a five-year brain tumor survivor and volunteer advocate with the National Brain Tumor Society, I want […]Read more |